Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04157335) enrolled 287 adults with chronic rhinosinusitis with nasal polyps — a condition where growths form inside the nose and sinuses, causing blockage and other symptoms. Participants were randomly assigned to receive either benralizumab (144 people) or a placebo (an inactive dummy treatment, 143 people) during a blinded phase lasting about 56 weeks, where neither participants nor their doctors knew who received which. The trial was primarily measuring two things: the size of nasal polyps as seen through a small camera (endoscopy), and how badly participants felt their nasal blockage was on a daily rating scale. The reported data shows that, at week 56, the polyp size score (rated 0–8, where higher means larger polyps) dropped by an average of 0.3 points in the benralizumab group and 0.1 points in the placebo group. For nasal blockage (rated 0–3, where higher means more severe), the average score fell by 0.64 points in the benralizumab group and 0.45 points in the placebo group. For the secondary measures, the reported data shows the smell difficulty score (0–3 scale) decreased by 0.26 versus 0.05; the sinus CT opacification score (0–24 scale) fell by 1.3 versus 0.7; and a broader quality-of-life score (0–110 scale) decreased by 18.0 versus 15.2 — all comparing benralizumab to placebo respectively. Regarding the time to a first nasal polyp surgery, the reported figures were approximately 6.3 months in the benralizumab group and 7.8 months in the placebo group, though what drove this difference is not explained in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 33710614) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Chronic Rhinosinusitis Trial, Terminated
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are a man or woman between 18 and 75 years old
- You have been using a nasal corticosteroid spray regularly and consistently for at least 4 weeks before joining, and are willing to continue using it throughout the study
- You have previously been treated with steroid tablets/injections or have had surgery for nasal polyps
- You have nasal polyps in both nostrils, with a combined polyp score of at least 5 (and at least 2 in each nostril individually), as measured by a doctor
- Your nasal polyp symptoms have been ongoing for at least 12 weeks before joining
- You report moderate to severe nasal blockage (confirm with trial site for exact scoring details)
- Your nasal blockage symptoms meet a certain level of severity over a two-week tracking period (confirm with trial site)
- Your quality-of-life score related to your sinus and nasal symptoms reaches a certain level at two separate points in the study (confirm with trial site)
- You have been diagnosed with asthma by a doctor
- Your blood test shows a higher-than-normal level of a type of white blood cell called eosinophils
- If you are of Asian background, your sinus scan results meet a specific threshold (confirm with trial site)
Who may not be able to join:
- You have had nasal or sinus surgery within the last 3 months
- You have certain nasal conditions that would make it difficult to properly assess the study's main goals, such as polyps on only one side of the nose, a severely deviated nasal septum blocking at least one nostril, overuse of nasal decongestant sprays, or a specific type of fungal sinus condition
- You have other serious health conditions involving the same type of white blood cell (eosinophils) that could affect your safety or make the study results harder to interpret
- You have taken steroid tablets or injections within 4 weeks before screening, or plan to take them during the study
- You have received any biologic medication (a type of specialist drug) — whether approved or experimental — within the last 6 months
- You are currently pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Luo Zhang, Prof. Dr., Beijing Tongren Hospital
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
3 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56; Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.